A Focused Specialty-Pharma Portfolio
Uniphar is building a portfolio around high-need therapeutic areas rather than pursuing a broad, undifferentiated generic portfolio.
Portfolio built around high-need areas
- Oncology – injectable and oral therapies
- Onco-hematology
- Targeted oncology therapies
- Biosimilars and complex biologics
- Rare and specialty disease opportunities
- Hospital and institutional products
- Supportive-care therapies
How we decide what to bring to market
Every opportunity is assessed against the same disciplined criteria.
Clinical relevance and unmet need
Reliable and qualified manufacturing
Regulatory feasibility
Commercial sustainability
Competitive positioning
Supply continuity
Long-term lifecycle potential
See our six-step value model
Learn moreExpanding into complex molecules
The portfolio may expand into selected monoclonal antibodies, biosimilars, complex peptides and other specialty products as licensing and regulatory pathways are established.
- Monoclonal antibodies
- Biosimilars
- Complex peptides
- Other specialty products
Specific products offered through Uniphar are presented separately based on finalized licensing, registration and supply arrangements. Product availability, licensing rights, registration status and territory rights are confirmed market by market. Individual products remain subject to regulatory approval, licensing and commercial arrangements in each territory.
Explore a Partnership
Let’s build the next generation of specialty pharmaceutical opportunities together.